OTC:VCNX
VACCINEX, INC.
A clinical-stage biotech firm developing novel vaccine platforms with significant cash burn and limited current revenue generation.
Key Metrics
Investment Thesis
Bull Case
VCNX offers a high-risk, high-reward opportunity for investors seeking exposure to breakthrough vaccine technologies before commercialization, potentially yielding substantial returns if clinical trials succeed and licensing deals materialize. The company's proprietary platform could revolutionize treatment options for infectious diseases, providing a first-mover advantage in an urgent global market.
Bear Case
The stock is highly speculative with no current revenue to sustain operations, resulting in a deep accumulated deficit of over $350M and negative shareholders' equity. Investors face the high probability of dilution through further equity raises or bankruptcy if the company cannot secure sufficient capital to fund its extensive R&D pipeline.
About VACCINEX, INC.
VACCINEX (VCNX) is a clinical-stage biopharmaceutical company focused on developing novel vaccine platforms and immunotherapies for infectious diseases. The company operates primarily in the global vaccine market, leveraging its proprietary technology to address unmet medical needs in high-priority therapeutic areas. With minimal revenue currently generated, the firm's financial profile reflects heavy investment in research and development activities.
Analysis
Management Discussion
Despite a massive cash burn of $18.6M in net loss, the company maintained a positive cash position of $1.1M at year-end, likely supported by recent financing events showing $15.7M in other financing cash flows. However, the lack of revenue growth and continued heavy spending on research and development indicate that the firm is still in the early investment phase with no immediate path to profitability.
Industry Overview
The global vaccine industry is currently undergoing a transformation driven by advancements in mRNA technology and the urgent need for next-generation immunotherapies against emerging pathogens. While the sector offers massive long-term growth potential, early-stage companies like VCNX face intense competition from established giants and significant regulatory hurdles before achieving commercial success.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $275.0K | $570.0K | $601.0K |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $275.0K | $570.0K | $601.0K |
| Operating Expenses | $20.2M | $23.5M | $19.3M |
| Operating Income | $-19.9M | $-22.9M | $-18.7M |
| R&D | $14.0M | $16.6M | $12.5M |
| G&A | $6.2M | $6.9M | $6.8M |
| Stock-Based Comp | $545.0K | $474.0K | $341.0K |
| Depreciation | $207.0K | $119.0K | $94.0K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $91.0K | $2.6M | $101.0K |
| Interest Expense | $2.0K | $1.0K | $2.0K |
| Pre-Tax Income | $-19.8M | $-20.3M | $-18.6M |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-19.8M | $-20.3M | $-18.6M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-19.8M | $-20.3M | $-18.6M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-19.8M | $-20.3M | $-18.6M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $7.5M | $3.3M | $2.5M |
| Cash & Equivalents | $6.4M | $1.5M | $1.1M |
| Accounts Receivable | $175.0K | $961.0K | $838.0K |
| Prepaid Expenses | $912.0K | $853.0K | $586.0K |
| Other Current Assets | $0 | $0 | $0 |
| Long-Term Assets | $499.0K | $282.0K | $65.0K |
| PP&E (Net) | $189.0K | $136.0K | $65.0K |
| Operating Leases | $310.0K | $146.0K | $0 |
| Other LT Assets | $0 | $0 | $0 |
| Total Assets | $8.0M | $3.6M | $2.6M |
| Current Liabilities | $2.5M | $5.9M | $5.1M |
| Accounts Payable | $1.5M | $2.0M | $4.0M |
| Current Debt | $74.0K | $75.0K | $25.0K |
| Current Leases | $164.0K | $146.0K | $0 |
| Deferred Revenue | — | $63.0K | $0 |
| Other Current Liab | $0 | $2.4M | $0 |
| Long-Term Liabilities | $247.0K | $26.0K | $0 |
| Long-Term Debt | $101.0K | $26.0K | $0 |
| LT Operating Leases | $146.0K | — | — |
| Other LT Liab | $0 | $0 | $0 |
| Total Liabilities | $2.8M | $5.9M | $5.1M |
| Shareholders' Equity | $5.2M | $-2.3M | $-2.5M |
| Retained Earnings | $-319.7M | $-339.9M | $-358.6M |
| Treasury Stock | $11.0K | $11.0K | $11.0K |
| Total L&E | $8.0M | $3.6M | $2.6M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-19.8M | $-20.3M | $-18.6M |
| Non-Cash Adjustments | $214.0K | $1.2M | $1.1M |
| Working Capital Changes | $527.0K | $1.8M | $1.3M |
| Cash from Operations | $-19.1M | $-17.2M | $-16.2M |
| Capital Expenditures | $99.0K | $67.0K | $22.0K |
| Cash from Investing | $-99.0K | $-67.0K | $-22.0K |
| Debt Repayments | $75.0K | $74.0K | $76.0K |
| Cash from Financing | $17.0M | $12.4M | $15.8M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-2.2M | $-4.9M | $-428.0K |
| Beginning Cash | $8.6M | $6.4M | $1.5M |
| Ending Cash | $6.4M | $1.5M | $1.1M |
Frequently Asked Questions
How does VACCINEX, INC. make money?
The company's operations are concentrated in a single primary segment: Vaccine Development and Immunotherapy. This segment encompasses all reported revenue, which stems from early-stage licensing agreements or grant funding rather than commercial product sales, supported by substantial R&D expenditures totaling $12.5M in the latest period.
What are the main risks for VCNX?
Major risks include the significant risk of total failure in high-risk R&D programs leading to zero commercial return, depletion of cash reserves given the $16.2M annual operating cash burn without current product revenue, dependence on external funding sources like equity issuance or grants, and the potential for clinical trial failures that could eliminate future value.
What is VCNX's competitive advantage?
The company's key strengths include proprietary vaccine platform technology that offers a potential head start against competitors, access to global markets through strategic partnerships typical of clinical-stage biotechs, and an agile organizational structure allowing for rapid adaptation to emerging infectious disease threats.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.